00:12:33South Africa

Replimune Group, Inc. (REPL)

NASDAQ

Key stats Fiscal year 2026

Income statement

Net income
-313,940,000
Operating income
-319,919,000
Earnings per share
-3.38
R&D expense
221,184,000

Growth and profitability

Return on equity
-188.94
Return on assets
-94.45

Balance sheet

Total assets
332,388,000
Total liabilities
166,228,000
Shareholders' equity
166,160,000
Cash and equivalents
209,024,000
Debt
83,308,000
Net debt
-125,716,000
Current ratio
4.79
Debt to equity
0.50

Cash flow and ratios

Operating cash flow
-280,344,000
Free cash flow
-284,567,000

Shareholder returns

Shares outstanding
94,800,404
Book value per share
1.75
Revenue and net income
Debt, free cash flow and cash
Earnings per share

Company information

Headquarters
Woburn, MA
Exchange
NASDAQ
Fiscal year end
03-31
Industry (SEC)
Biological Products, (no Diagnostic Substances)

Fiscal year end: · Source: SEC EDGAR

Replimune Group, Inc. trades on NASDAQ under the ticker symbol REPL. This page brings together its price chart, company profile, key financial figures and technical indicators.

Company profile

Technical analysis